Recently, the Shuangjing Community Health Service Center in Beijing’s Chaoyang District—commonly referred to as ‘Shuangjing Hospital’—was penalized by market regulators for using substandard drugs, drawing public attention. According to a notice from the Beijing Municipal Drug Administration, the facility procured and administered pharmaceutical products that failed to meet national drug standards. Subsequent inspections confirmed these products as substandard.Under the relevant provisions of China’s Drug Administration Law, authorities have imposed a fine, ordered an immediate halt to the use of the problematic drugs, and mandated comprehensive reforms to the institution’s drug procurement and management systems.This incident highlights ongoing vulnerabilities in drug quality control at some grassroots medical institutions, such as inadequate vetting of suppliers and superficial incoming goods inspections. Regulators stressed that healthcare providers, as the final point of drug administration, must strictly fulfill their responsibilities to ensure patient safety. The public is also encouraged to remain vigilant and report any suspicious medications to authorities.Shuangjing Hospital has cooperated with the investigation and implemented initial corrective measures, with responsible personnel held accountable. Drug regulators affirmed their commitment to intensifying oversight of community-level medical facilities and cracking down on violations to safeguard public health.
近日，北京市朝阳区双井社区卫生服务中心（俗称‘双井医院’）因使用劣药被市场监管部门依法处罚，引发社会关注。据北京市药品监督管理局通报，该医疗机构在日常诊疗过程中采购并使用了不符合国家药品标准的制剂，经抽检确认为劣药。依据《中华人民共和国药品管理法》相关规定，监管部门已对其处以罚款，并责令立即停止使用问题药品、全面整改药品采购与管理制度。此次事件暴露出部分基层医疗机构在药品质量管理方面仍存在漏洞，如供应商审核不严、进货查验流于形式等。监管部门强调，医疗机构作为药品使用终端，必须严格落实主体责任，确保患者用药安全。同时，公众也应提高警惕，若发现药品异常可及时向药监部门举报。目前，双井医院已配合调查并完成初步整改，相关责任人被问责。药监部门表示将持续加强对基层医疗机构的监督检查，严打违法违规行为，切实保障人民群众用药安全。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/3953.html